Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × efaproxiral × Clear all
NCT00004202 2021-08-26

Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00055887 2013-05-10

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Spectrum Pharmaceuticals, Inc

Phase 3 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡